MarketCap
Facebook
X
Telegram
Country |
 USA |
IPO year |
2021 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
4.25 M |
Market Cap[1] |
$ 2.85 M |
EBITDA (LTM) |
- |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Catalyst Biosciences
CBIO
|
$ 11.84 | 0.87 % | $ 1.06 B | Nasdaq Capital Market | USA |
 |
Seagen
SGEN
|
- | - | $ 42.2 B | Nasdaq Global Select Market,SPB | USA |
 |
Codexis
CDXS
|
$ 1.24 | 5.43 % | $ 108 M | Nasdaq Global Select Market | USA |
 |
Cullinan Management
CGEM
|
$ 12.93 | 2.64 % | $ 779 M | Nasdaq Global Select Market | USA |
 |
Compugen Ltd.
CGEN
|
$ 1.96 | 4.0 % | $ 183 M | Nasdaq Global Market,SPB |  Israel |
 |
Cellectar Biosciences
CLRB
|
$ 1.14 | 0.84 % | $ 2.97 M | Nasdaq Capital Market | USA |
 |
Amarin Corporation plc
AMRN
|
$ 11.32 | 0.17 % | $ 4.7 B | Nasdaq Global Market |  Irlanda |
 |
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | USA |
 |
Cocrystal Pharma
COCP
|
$ 1.02 | 0.49 % | $ 11.5 M | Nasdaq Capital Market | USA |
 |
Aclaris Therapeutics
ACRS
|
$ 3.28 | 3.25 % | $ 402 M | Nasdaq Global Select Market | USA |
 |
Collegium Pharmaceutical
COLL
|
$ 23.19 | 0.04 % | $ 734 M | Nasdaq Global Select Market | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
$ 4.52 | 4.39 % | $ 60.2 M | Nasdaq Global Market | USA |
 |
Curis
CRIS
|
$ 0.41 | 1.4 % | $ 5.4 M | Nasdaq Global Market | USA |
 |
Corvus Pharmaceuticals
CRVS
|
$ 9.52 | 5.01 % | $ 752 M | Nasdaq Global Market | USA |
 |
Vascular Biogenics Ltd.
VBLT
|
- | -8.77 % | $ 12.4 M | Nasdaq Global Select Market | Israel |
 |
Berkeley Lights
BLI
|
- | -7.31 % | $ 87 M | Nasdaq Global Select Market | USA |
 |
Histogen
HSTO
|
- | 31.6 % | $ 2.12 M | Nasdaq Global Select Market | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
$ 24.02 | 0.39 % | $ 3.64 B | Nasdaq Global Select Market,SPB | USA |
 |
Denali Therapeutics
DNLI
|
$ 17.61 | 2.63 % | $ 3.04 B | Nasdaq Global Select Market,SPB | USA |
 |
Achieve Life Sciences
ACHV
|
$ 6.38 | 0.79 % | $ 278 M | Nasdaq Capital Market | USA |
 |
ImmunoGen
IMGN
|
- | - | $ 7.92 B | Nasdaq Global Select Market | USA |
 |
Precision BioSciences
DTIL
|
$ 5.77 | 2.32 % | $ 74 M | Nasdaq Global Select Market | USA |
 |
Editas Medicine
EDIT
|
$ 2.35 | 7.49 % | $ 209 M | Nasdaq Global Select Market,SPB | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
$ 84.95 | 0.13 % | $ 7.99 B | Nasdaq Global Select Market | USA |
 |
Agios Pharmaceuticals
AGIO
|
$ 31.32 | 4.36 % | $ 1.82 B | Nasdaq Global Select Market,SPB | USA |
 |
Enanta Pharmaceuticals
ENTA
|
$ 11.1 | 2.59 % | $ 237 K | Nasdaq Global Select Market,SPB | USA |
 |
Exelixis
EXEL
|
$ 62.23 | 0.06 % | $ 16.9 B | Nasdaq Global Select Market,SPB | USA |
 |
EyePoint Pharmaceuticals
EYPT
|
$ 2.99 | 4.32 % | $ 219 K | Nasdaq Global Market | USA |
 |
AIM ImmunoTech
AIM
|
$ 0.17 | 1.53 % | $ 275 K | NYSE American | USA |
 |
Cidara Therapeutics
CDTX
|
- | - | $ 1.41 B | Nasdaq Global Market | USA |
 |
Iterum Therapeutics
ITRM
|
- | - | $ 591 K | Nasdaq Global Select Market | Irlanda |
 |
Akebia Therapeutics
AKBA
|
$ 0.67 | 0.14 % | $ 172 M | Nasdaq Global Market | USA |
 |
GlaxoSmithKline plc
GSK
|
$ 49.51 | 1.0 % | $ 201 B | NYSE |  Britain |
 |
GT Biopharma
GTBP
|
$ 7.03 | 18.52 % | $ 38.8 M | Nasdaq Capital Market | USA |
 |
Heron Therapeutics
HRTX
|
$ 0.36 | 4.01 % | $ 60 M | Nasdaq Global Select Market,SPB | USA |
 |
Johnson & Johnson
JNJ
|
$ 255.56 | 0.86 % | $ 615 B | NYSE,SPB | USA |
 |
Akari Therapeutics, Plc
AKTX
|
$ 8.18 | 19.02 % | $ 551 B | Nasdaq Capital Market | Britain |
 |
Clovis Oncology
CLVS
|
- | -7.23 % | $ 13 M | Nasdaq Global Select Market | USA |
 |
Arcutis Biotherapeutics
ARQT
|
$ 28.82 | 10.19 % | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
Aldeyra Therapeutics
ALDX
|
$ 0.7 | 0.62 % | $ 42 M | Nasdaq Global Select Market | USA |
 |
Kura Oncology
KURA
|
$ 9.08 | 0.94 % | $ 796 M | Nasdaq Global Select Market | USA |
 |
Concert Pharmaceuticals
CNCE
|
- | - | $ 401 M | Nasdaq Global Market | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
- | - | $ 231 M | Nasdaq Global Market | USA |
 |
Kaleido Biosciences
KLDO
|
- | -3.69 % | $ 12.4 M | Nasdaq Global Select Market | USA |
 |
Cyclerion Therapeutics
CYCN
|
$ 34.99 | 3.77 % | $ 147 M | Nasdaq Global Select Market | USA |
 |
Alector
ALEC
|
$ 1.84 | 6.02 % | $ 190 M | Nasdaq Global Select Market,SPB | USA |
 |
ObsEva SA
OBSV
|
- | -15.52 % | $ 10.5 M | Nasdaq Global Select Market |  Schweiz |
 |
Kronos Bio
KRON
|
- | 1.49 % | $ 50.8 M | Nasdaq Global Select Market | USA |
 |
Landos Biopharma
LABP
|
- | 0.58 % | $ 144 M | Nasdaq Global Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.